Insights from "EVER-Vilda", Expert Perspective on Vildagliptin's Applicability in Indian T2DM Patients

The "EVER-Vilda" opinion paper is an Indian expert's evaluation of the efficacy and rationality of vildagliptin. It underscores vildagliptin's versatile applicability, safety and provides practical guidance for healthcare professionals regarding the use of Vildagliptin in T2DM care.

This expert consensus article has been published in the February 2024 issue of the Journal of Clinical Medicine Insights: Endocrinology and Diabetes.

A panel of 25 experts, including endocrinologists, diabetologists, and cardiologists from India, convened for two advisory board meetings to discuss the various roles and combinations of vildagliptin in managing T2DM.

Some of the final consensus statements include:

1. Vildagliptin 100mg SR OD is a practical therapeutic alternative to 50mg IR BID formulation to improve adherence and persistence.

2. Vildagliptin 100mg SR OD dose is equally effective as 50mg twice daily vildagliptin regarding HBA1c, fasting, and postprandial blood glucose levels.

Adapted from:

1. Kalra S, Zargar AH, Sridhar G, et al. Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective. Clinical Medicine Insights: Endocrinology and Diabetes. 2024;17. doi:10.1177/11795514231203911